TLDR
- Stryker reported Q1 profit of $745 million, up from $654 million a year ago
- Revenue of $6.02 billion missed analyst estimates of $6.35 billion
- Adjusted EPS of $2.60 fell short of the $2.98 consensus estimate
- An Iranian-linked cyberattack in March disrupted operations and impacted results
- SYK stock fell roughly 2% in after-hours trading to $308.75; full-year guidance was maintained
Stryker posted a mixed first quarter, beating on profit year-over-year but missing Wall Street’s top and bottom line estimates. The results were complicated by a cyberattack the company absorbed in March.
$SYK | Stryker Corp., Q1-2026 Earning Report pic.twitter.com/yvh17fBaD9
— Hardik Shah (@AIStockSavvy) April 30, 2026
SYK stock dropped about 2% in after-hours trading to $308.75 following the report.
The company earned $745 million in net profit, or $1.93 per share, up from $654 million, or $1.69 per share, in Q1 2025. On an adjusted basis, Stryker earned $2.60 per share, missing the $2.98 analysts had expected.
Total revenue came in at $6.02 billion for the quarter ended March 31. That was a 2.6% increase year-over-year but fell short of the $6.35 billion consensus estimate.
Cyberattack Clouded the Quarter
In March, an Iranian-linked hacking group called Handala claimed responsibility for a destructive cyberattack on Stryker. The attack caused widespread disruptions to the company’s Microsoft systems and reportedly delayed some surgical procedures.
Some staff and contractors posted on social media that the hacking group’s logo appeared on their login screens, though Reuters was unable to independently verify those claims.
Stryker had flagged earlier in April that the incident would weigh on first-quarter results. The company confirmed that on Thursday.
The hackers said they were acting in retaliation over the escalating conflict between the U.S. and Iran, according to a Wall Street Journal report at the time.
Segment Results Mixed
Stryker’s MedSurg and Neurotechnology segment, its largest, posted a 5% sales increase to $3.21 billion. That missed analyst estimates of $3.83 billion.
The Orthopaedics segment was a relative bright spot. Sales rose 6.3% to $2.81 billion, beating the $2.51 billion analysts had penciled in.
Softer demand for implants and devices used in complex procedures — including spinal and orthopedic surgeries — weighed on the overall numbers.
Stryker competes directly with Zimmer Biomet (ZBH) and Johnson & Johnson (JNJ) in the orthopaedics market, across segments like hip and knee replacements, trauma, and sports medicine.
Despite the quarter’s shortfalls, Stryker held its full-year guidance. The company reiterated expectations for adjusted annual profit in the range of $14.90 to $15.10 per share.
The maintained outlook signals management’s view that the cyberattack’s financial impact is contained to Q1 and won’t affect the broader year.
Stryker’s adjusted EPS of $2.60 for Q1 compared to full-year guidance of $14.90–$15.10 per share implies the company expects a stronger pace of earnings in the remaining three quarters.
Stryker reiterated its full-year adjusted EPS guidance range of $14.90 to $15.10 per share.
🚨 Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
